Tizanidine: Clinical Overview
Tizanidine is FDA-approved for short-term management of spasticity, particularly effective in chronic stroke patients, with dosing titrated from 2-4 mg initially up to 36 mg/day divided into multiple doses, though it should be reserved for specific daily activities requiring spasticity relief due to its short duration of action. 1
Primary Indications
Tizanidine is an α2-adrenergic receptor agonist (clonidine derivative) classified as a centrally acting spasmolytic agent 2. The evidence supports its use specifically for:
- Chronic stroke-related spasticity (strongest evidence) - particularly when causing pain, poor skin hygiene, or decreased function 3
- Spinal cord injury spasticity 4
- Multiple sclerosis-related spasticity 5
- Acquired brain injury spasticity 6
The 2005 Stroke guidelines specifically recommend tizanidine for chronic stroke patients, distinguishing it from other antispastic agents 3. Open-label studies in chronic stroke patients demonstrated significant improvements in spasticity and pain without loss of motor strength 7.
Dosing Strategy
Start at 2-4 mg daily and titrate slowly over 2-4 weeks to effect, with maximum dose of 36 mg/day in divided doses 2, 1. The wide interpatient variability in effective plasma concentrations necessitates individualized titration 8, 9.
Key dosing principles:
- Maximum effects occur within 2 hours of administration 8
- Short duration of action requires multiple daily doses (typically 3-4 times daily) 1
- Average effective dose in clinical trials: 25.2 mg/day 6
- Only 21% of patients tolerate maximum 36 mg/day dose 7
- Reserve use for specific daily activities and times when spasticity relief is most critical 1
Critical Precautions and Contraindications
Absolute Contraindications
- Concurrent use with ciprofloxacin or fluvoxamine (significantly reduces tizanidine clearance) 2
Avoid or Use Extreme Caution In:
- Hepatic dysfunction 2
- Renal dysfunction 2
- Elderly patients (due to significant sedative and hypotensive effects) 2
Significant Drug Interactions (CYP1A2 Inhibitors)
Risk of severe hypotension, bradycardia, and sedation with 2:
- Oral contraceptives
- Acyclovir
- Amiodarone
- Verapamil
- Cimetidine
- Famotidine
Withdrawal Risk
Never discontinue abruptly in long-term users - taper slowly to avoid withdrawal syndrome including 2:
- Rebound tachycardia
- Hypertension
- Hypertonia
The perioperative guideline explicitly recommends continuing tizanidine through the day of surgery to prevent withdrawal 2.
Common Adverse Effects
The most frequent adverse effects are dose-dependent 2, 1:
Very Common (>40%):
- Dry mouth (49%)
- Somnolence/sedation (48%)
- Asthenia (weakness/fatigue) (41%)
Common (10-20%):
- Dizziness (16%)
- Hypotension (16-33% in single-dose studies)
- Bradycardia (10% in single-dose studies)
Other Notable Effects:
- Ataxia
- Lethargy
- Elevated liver function tests (3%)
Approximately 17% of patients discontinue treatment due to adverse effects, most commonly asthenia, somnolence, dry mouth, or dizziness 1.
Clinical Advantages Over Alternatives
Tizanidine preserves muscle strength better than baclofen or diazepam - a critical distinction for functional outcomes 8, 7, 6. Studies show:
- Subjective muscle weakness reported less frequently than with baclofen 8
- No objective decline in muscle strength despite reduced tone 7, 6
- Global tolerability rated good-to-excellent in 44-100% vs. 20-54% for diazepam 8
The 2005 Stroke guidelines recommend against benzodiazepines during stroke recovery due to deleterious effects on recovery, making tizanidine a preferred alternative 3.
Perioperative Benefits
Emerging evidence supports perioperative continuation, showing 2:
- Improved postoperative pain control
- Decreased midazolam requirements
- Reduced opioid consumption
- Hemodynamic stability
Stepwise Treatment Approach
Per stroke rehabilitation guidelines, treat spasticity in this order 3:
- Non-pharmacologic first: Positioning, range of motion exercises, stretching, splinting, serial casting
- Oral medications: Tizanidine, dantrolene, or baclofen for spasticity causing pain, hygiene issues, or functional impairment
- Focal interventions: Botulinum toxin or phenol/alcohol for localized spasticity
- Intrathecal baclofen: For chronic stroke patients with refractory spasticity
- Neurosurgical procedures: Selective dorsal rhizotomy or dorsal root entry zone lesions (last resort)
Key Clinical Pitfalls
- Do not use for acute stroke - evidence supports use specifically in chronic stroke (>6 months post-event) 3, 7
- Monitor for hepatotoxicity - though generally reversible and not serious 10
- Expect high interpatient variability - plasma concentrations vary widely despite linear pharmacokinetics 9
- Central nervous system depression - particularly problematic when combined with opioids or other CNS depressants 2, 10